AMPH (Amphastar Pharmaceuticals) Other Long-Term Liabilities: $29.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMPH Amphastar Pharmaceuticals Inc AMPH
84 GF Score
Price $19.93
GF Value $49.09
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Other Long-Term Liabilities?

Amphastar Pharmaceuticals AMPH -2.06% 84 Other Long-Term Liabilities is $29.4 Mil as of Mar. 2026. GuruFocus rates AMPH with a GF Score™ of 84/100 and a GF Value™ of $49.09 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Amphastar Pharmaceuticals's other long-term liabilities for the quarter that ended in Mar. 2026 was $29.4 Mil.

Amphastar Pharmaceuticals's quarterly other long-term liabilities increased from Sep. 2025 ($29.3 Mil) to Dec. 2025 ($30.0 Mil) but then declined from Dec. 2025 ($30.0 Mil) to Mar. 2026 ($29.4 Mil).

Amphastar Pharmaceuticals's annual other long-term liabilities declined from Dec. 2023 ($22.7 Mil) to Dec. 2024 ($20.9 Mil) but then increased from Dec. 2024 ($20.9 Mil) to Dec. 2025 ($30.0 Mil).

Amphastar Pharmaceuticals Other Long-Term Liabilities Related Terms

Amphastar Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals Other Long-Term Liabilities Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.65 14.57 22.72 20.95 29.98

Amphastar Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.42 27.80 29.27 29.98 29.36
AMPH
84GF Score
Amphastar Pharmaceuticals Inc AMPH
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $29.4 Mil mean?
Amphastar Pharmaceuticals (AMPH) has a Other Long-Term Liabilities of $29.4 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Amphastar Pharmaceuticals and its competitors.
Is Amphastar Pharmaceuticals' Other Long-Term Liabilities too high?
Amphastar Pharmaceuticals' current Other Long-Term Liabilities is $29.4 Mil. Overall, Amphastar Pharmaceuticals has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Other Long-Term Liabilities compare to ESPR and NIKA?
Amphastar Pharmaceuticals' Other Long-Term Liabilities of $29.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Other Long-Term Liabilities is $29.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.09, compared to a current price of $19.93 — trading 59.4% below its estimated fair value. The current Other Long-Term Liabilities is $29.4 Mil. Amphastar Pharmaceuticals' overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Other Long-Term Liabilities is $29.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $19.93 is trading 59.4% below its estimated GF Value™ of $49.09. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Other Long-Term Liabilities: $29.4 Mil
  • GF Value™: $49.09 vs. price of $19.93 (59.4% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
84GF Score

Get the complete analysis for AMPH

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.93
Price
$49.09
GF Value